Redwood Pharma

One of the world's largest conferences in the field of ophthalmology, ARVO, takes place in Seattle, USA, on May 5-9. During the conference, Assoc. Prof. Dr. Gerhard Garhöfer, principal investigator for Redwood Pharma's clinical study with the medical device RP501, presents the results of the study during a poster presentation.

"I am very pleased with the positive response from the conference attendees, especially for the clinical results of the study which showed that RP501 has a unique mechanism of action and an innovative formulation that can help people suffering from mild to moderate dry eye. RP501 has strong potential to meet the high demand for clinical efficacy and ease of use that consumers demand," says Assoc. Prof. Dr. Gerhard Garhöfer at the Medical University of Vienna.

RP501 is being developed to be an effective and user-friendly over-the-counter thermogel for the temporary relief of dry eye, a condition that affects more than 300 million people worldwide. The results of a clinical study show that RP501 is safe, provides a significant therapeutic effect already at a dosage of 1-2 drops per day and is convenient to use - characteristics that consumers consider the most important parameters for a dry eye product.

The study was completed in the spring of 2023 and is presented at ARVO under the title: "Assessment of safety, tolerability and efficacy of RP501 eye drops in patients with dry eye disease and subjects wearing contact lenses with lens discomfort."

For more information:

Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.com

About Redwood Pharma

Redwood Pharma AB (publ) (Nasdaq First North Growth Market: REDW) develops next-generation treatments for dry eye. More than 300 million people suffer from dry eyes and today's standard treatment provides only temporary relief and may need to be applied more than ten times a day. Redwood Pharma's programs are based on IntelliGel - a patented and unique formulation of polymers and water that has the consistency of a drop of water when dropped into the eye, where it immediately forms a viscous, protective and lubricating film that remains for a long time. The company is currently pursuing two development projects: RP501 as a readily available medical device for the first line treatment of dry eye, and the drug candidate RP101 that contains estrogen for the treatment of women who suffer from dry eye after menopause. The company's Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm (+46 8 463 80 00, certifidadviser@penser.se). For more information, visit www.redwoodpharma.com